Liver Abscess in a Pediatric Patient with Ulcerative Colitis: A Case Presentation

Daniel F Castillo1, Ricardo Caicedo2, Vani Gopalareddy2

  • 1Department of Pediatrics, Atrium Health- Levine Children's Hospital, Charlotte, NC, USA.

Insights

This study reports the first pediatric case of hepatic abscesses and portal vein thrombosis in a patient with ulcerative colitis (UC). The findings highlight a rare but serious complication of inflammatory bowel disease in children.

Area of Science:

  • Gastroenterology
  • Hepatology
  • Pediatrics

Background:

  • Hepatic abscesses are rare extra-intestinal manifestations of inflammatory bowel disease (IBD).
  • The risk stratification for hepatic abscesses in Crohn's disease versus ulcerative colitis (UC) remains debated.
  • Hepatic abscesses in pediatric patients with UC are exceptionally rare, with no prior reported cases.

Observation:

  • This report details a pediatric patient diagnosed with UC who subsequently developed hepatic abscesses and portal vein thrombosis.
  • The patient experienced an extended period of UC remission without immunosuppressive therapy.
  • The clinical course and therapeutic interventions are analyzed for potential contributions to the observed complications.

Findings:

  • The case presents the first documented instance of hepatic abscesses and portal vein thrombosis in a pediatric patient with UC.
  • This occurrence challenges the existing understanding of UC as a risk factor for hepatic abscesses in pediatric populations.
  • The patient's prolonged remission and treatment modifications offer unique insights into disease management and complication development.

Implications:

  • This case underscores the importance of considering hepatic abscesses as a potential complication in pediatric IBD, particularly UC.
  • Further research is warranted to elucidate the specific risk factors and mechanisms linking UC to hepatic abscesses in children.
  • Clinical management strategies for pediatric IBD may need re-evaluation to address the risk of such rare but severe complications.

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
953
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
483
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
276
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
203
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
262